CN115279459A - 使用针对bcma和cd3的抗体的治疗方法 - Google Patents

使用针对bcma和cd3的抗体的治疗方法 Download PDF

Info

Publication number
CN115279459A
CN115279459A CN202080091830.3A CN202080091830A CN115279459A CN 115279459 A CN115279459 A CN 115279459A CN 202080091830 A CN202080091830 A CN 202080091830A CN 115279459 A CN115279459 A CN 115279459A
Authority
CN
China
Prior art keywords
antibody
ser
seq
region
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091830.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·伯格斯
K·赫格
K·达塔
I·波斯
M·D·武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN115279459A publication Critical patent/CN115279459A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080091830.3A 2019-11-05 2020-11-04 使用针对bcma和cd3的抗体的治疗方法 Pending CN115279459A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP19207293.2 2019-11-05
EP20179573.9 2020-06-11
EP20179573 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
CN115279459A true CN115279459A (zh) 2022-11-01

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091830.3A Pending CN115279459A (zh) 2019-11-05 2020-11-04 使用针对bcma和cd3的抗体的治疗方法

Country Status (11)

Country Link
US (1) US20230057602A1 (https=)
EP (1) EP4054725A4 (https=)
JP (1) JP7792333B2 (https=)
KR (1) KR20220093141A (https=)
CN (1) CN115279459A (https=)
AU (1) AU2020379757A1 (https=)
BR (1) BR112022008516A2 (https=)
CA (1) CA3160137A1 (https=)
IL (1) IL292704A (https=)
MX (1) MX2022005292A (https=)
WO (1) WO2021092056A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
LT3819007T (lt) 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
CN121712524A (zh) * 2023-08-18 2026-03-20 百时美施贵宝公司 包含结合bcma和cd3的抗体的组合物以及治疗方法
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
AU2024390850A1 (en) * 2023-12-01 2026-04-02 Teneoone, Inc. Methods for the treatment of multiple myeloma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275787A1 (en) * 2008-10-01 2011-11-10 Microment AG Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2017021450A1 (en) * 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
CN110167964A (zh) * 2016-11-02 2019-08-23 英格玛布有限责任公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275787A1 (en) * 2008-10-01 2011-11-10 Microment AG Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2017021450A1 (en) * 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
CN108350073A (zh) * 2015-08-03 2018-07-31 英格玛布有限责任公司 针对bcma的单克隆抗体
CN110167964A (zh) * 2016-11-02 2019-08-23 英格玛布有限责任公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物

Also Published As

Publication number Publication date
EP4054725A1 (en) 2022-09-14
MX2022005292A (es) 2022-08-10
BR112022008516A2 (pt) 2022-08-30
IL292704A (en) 2022-07-01
AU2020379757A1 (en) 2022-05-26
WO2021092056A1 (en) 2021-05-14
KR20220093141A (ko) 2022-07-05
EP4054725A4 (en) 2024-01-10
JP7792333B2 (ja) 2025-12-25
JP2022553822A (ja) 2022-12-26
CA3160137A1 (en) 2021-05-14
US20230057602A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP7792333B2 (ja) Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
KR102364383B1 (ko) 삼중-특이적 결합 분자 및 그것의 사용 방법
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
WO2021092060A1 (en) Methods of treatment
AU2023375177A1 (en) Methods of treating cancers
JP2021524451A (ja) 最適化済みｇｐ４１結合分子及びその使用
TW202200615A (zh) 用於治療和預防患者的crs之方法
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
TW202220691A (zh) 用於使用ＰＤ—１ｘＣＴＬＡ—４雙特異性分子的方法
US20230172923A1 (en) Methods of treating cytokine-related adverse events
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
WO2025042742A1 (en) Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
KR20260057078A (ko) Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
HK40092434A (zh) Btla抗体
CN121925428A (zh) 结合突变钙网蛋白的分子及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083315

Country of ref document: HK